Phase 1, first-in-human, clinical study to assess the safety, pharmacokinetics and pharmacodynamics of ADX-097

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 15 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ADX-097 (Primary)
Indications IgA nephropathy; Lupus nephritis; Membranoproliferative glomerulonephritis; Skin disorders
Focus Adverse reactions; First in man
Sponsors Q32 Bio

14 Oct 2024 According to a Q32 Bio media release, company announced that it will present clinical data from this trial as poster presentation at the American Society of Nephrology (ASN) Kidney Week 2024, taking place October 24-27, 2024, in San Diego, Calif. This results support Phase 2 dose selection and continued clinical advancement of ADX-097.
09 May 2024 According to a Q32 Bio media release, Topline results from this study expected in the second half of 2025, with initial open-label renal basket data expected by year-end 2024.
24 Oct 2023 Status changed from recruiting to completed, according to a Q32 Bio media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com